Eli Lilly has experienced a surge in demand for its weight loss and diabetes treatments, propelling the company to new heights. The outgoing CFO, Anat Ashkenazi, played a crucial role in managing the success of their diabetes injection Mounjaro and obesity drug Zepbound. Despite challenges in supply shortages alongside Novo Nordisk, Eli Lilly's revenue boom has fueled investments in manufacturing to meet escalating demand. The company's focus on understanding the industry and navigating the system efficiently reflects Ashkenazi's proactive approach in bringing value to the business. With revenue reinvestment into manufacturing facilities, Eli Lilly aims to increase patient access to their life-changing medications. While challenges in meeting demand persist, the company's progress indicates promising future growth potential in the lucrative market of GLP-1 agonists.